Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 931 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Orthomyxoviridae Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

2017 A/H7N9 IIV Revaccination

NCT03738241
View directory record Official record
Conditions
Avian Influenza, Influenza Immunisation
Interventions
A/H7N9, AS03, Phosphate Buffered Saline (PBS) diluent
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years to 70 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Not applicable Interventional Results available

Patient Portal Flu Vaccine Reminders (5)

NCT05525494
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Text Fixed R/R Messages with Direct Appointment Schedule Link, Text Pre-Appointment Reminder, Portal Pre-Commitment Prompt with Tailored R/R Messages with Direct Appointment Schedule Link, Portal Fixed R/R Messages with Direct Appointment Schedule Link, Portal Pre-Appointment Reminder
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months and older
Enrollment
262,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older

NCT01992094
View directory record Official record
Conditions
Influenza
Interventions
QIVc, TIV1c, TIV2c
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
18 Years and older
Enrollment
2,680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
40
States / cities
Huntsville, Alabama • Phoenix, Arizona • Anaheim, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 16, 2026, 9:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

NCT05765396
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
Interventions
imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 16, 2026, 9:58 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity

NCT01421888
View directory record Official record
Conditions
Argininosuccinic Aciduria, Carbamoyl-Phosphate Synthase I Deficiency, Citrullinemia, Ornithine Carbamoyltransferase Deficiency, Hyperargininemia, N-Acetylglutamate Synthase Deficiency
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 99 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Immune Response to High-Dose vs. Standard Dose Influenza Vaccine

NCT02297542
View directory record Official record
Conditions
Elderly Immune System
Interventions
Flu Vaccine
Biological
Lead sponsor
Health Sciences North Research Institute
Other
Eligibility
20 Years and older
Enrollment
393 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

NCT01436370
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Sulforaphane (SFN) on Immune Response to Live Attenuated Influenza Virus in Smokers and Nonsmokers

NCT01269723
View directory record Official record
Conditions
Smoking
Interventions
Broccoli sprout homogenate, Alfalfa sprout homogenate
Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 40 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 29, 2014 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine

NCT02222870
View directory record Official record
Conditions
Influenza
Interventions
Fluzone® Quadrivalent Influenza Vaccine, No Preservative
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 8 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 1 Interventional

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients

NCT02267733
View directory record Official record
Conditions
Influenza, Gammopathy
Interventions
Fluzone
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

NCT05624606
View directory record Official record
Conditions
Influenza Immunization
Interventions
Quadrivalent Influenza mRNA Vaccine MRT5410, Quadrivalent Recombinant Influenza vaccine RIV4, Quadrivalent Inactivated Influenza Standard Dose QIV-SD, Quadrivalent Inactivated Influenza High Dose QIV-HD
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
23
States / cities
Huntington Park, California • Long Beach, California • North Hollywood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

NCT01416571
View directory record Official record
Conditions
Influenza
Interventions
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Pregnant Women From Infectious Diseases

NCT01761799
View directory record Official record
Conditions
Influenza, Pertussis
Interventions
P3 Vaccine Promotion Package.
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
11
States / cities
Athens, Georgia • Atlanta, Georgia • Bogart, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT06431607
View directory record Official record
Conditions
Influenza, Human
Interventions
F2G22B/DL001Z, F2H23D/DL001Z-NH, F2H23B/DL001Z-NH, F2H23H/DL001Z, FDQ23A-NH (Flu D-QIV), GSK5800544A, Flu D-TIV, F2H23A/DL001Z-NH, F2H23G/DL001Z, Fluzone HD Quadrivalent, Fluzone HD
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
845 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
18
States / cities
Hialeah, Florida • Miami, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

NCT01258530
View directory record Official record
Conditions
Influenza, Human
Interventions
over-encapsulated oseltamivir, oseltamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 16, 2026, 9:58 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

NCT02385123
View directory record Official record
Conditions
Influenza, Influenza Immunisation
Interventions
Influenza Virus Vaccine Inactivated
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

NCT03282240
View directory record Official record
Conditions
Influenza
Interventions
QIV-HD, Licensed TIV-HD1, Investigational TIV-HD2
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
2,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
36
States / cities
Anaheim, California • Redding, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 16, 2026, 9:58 AM EDT
Terminated Not applicable Interventional Results available

Patient Portal Flu Vaccine Reminders_RCT 4

NCT05052190
View directory record Official record
Conditions
Influenza, Respiratory Tract Infections
Interventions
Text Message R/R with Direct Appointment Schedule Link, Text Message R/R without Direct Appointment Schedule Link, Text Pre-Appointment Reminder, Portal Message R/R with Direct Appointment Schedule Link, Portal Message R/R without Direct Appointment Schedule Link, Portal Pre-Appointment Reminder
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Months and older
Enrollment
239,567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

NCT01181323
View directory record Official record
Conditions
Influenza
Interventions
Placebo, Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Testing of Influenza Vaccine in Healthy Children 2 Months and 6 Months of Age

NCT00858468
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (2004-2005 Formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Months to 9 Months
Enrollment
394 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
8
States / cities
Little Rock, Arkansas • Marietta, Georgia • Durham, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants

NCT04471038
View directory record Official record
Conditions
Influenza Type A, Influenza Type B, Influenza
Interventions
SAB-176, Normal Saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

NCT03028974
View directory record Official record
Conditions
Influenza
Interventions
Fluzone®, FluMist®
Biological
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 49 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Higher Dose Intradermal H5 Vaccine

NCT00439335
View directory record Official record
Conditions
Influenza
Interventions
Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID)
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Oct 16, 2026, 9:58 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

NCT04610047
View directory record Official record
Conditions
Influenza, Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • DeBary, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 16, 2026, 9:58 AM EDT